GRAIL, Inc. — Cyborg Score 5/10

Strategic Profile

GRAIL leverages a targeted methylation-based platform supporting the continuum of care from screening to precision oncology, including minimal residual disease detection and treatment monitoring. The company is positioned as a leader in multi-cancer early detection (MCED), with revenue growing 17% to $147.2M in 2025, though it remains unprofitable as it scales commercial adoption.

Cyborg Score Rationale

GRAIL shows strong clinical positioning and analyst support (Strong Buy consensus), with improving financial trajectory and 110% stock performance over past year. However, recent NHS-Galleri trial failure in February 2026 to meet primary endpoints for stage 3-4 cancer reduction creates significant headwinds, driving 50% stock decline and raising questions about commercial viability.

Top Insights

• Multi-cancer early detection (MCED) targeting massive TAM with aging demographics driving screening demand
• Recent NHS-Galleri trial failure represents critical inflection point requiring strategy reassessment
• Revenue growth accelerating (26% Q3 YoY) with $147.2M total 2025 revenue as commercial adoption scales
• Loss margin improvement: 2025 losses down 80% YoY to $408.4M despite continued heavy R&D investment

Named Competitors

• Shield — Multi-cancer early detection test for asymptomatic adults
• Tempus Platform — AI-powered precision oncology and cancer diagnostics
• FoundationOne — Comprehensive genomic profiling for cancer treatment

Recent Developments

• (March 2026) Announced equity grants for 20 newly hired non-executive employees, signaling continued hiring
• (February 2026) NHS-Galleri trial failed to meet primary endpoint for reducing stage 3-4 cancer detection, triggering 50% stock decline
• (January 2026) FDA submission announced for early cancer detection indication

Open the full interactive GRAIL, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.